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Abstract
The role of CD44 in the progression of human melanoma has mostly been characterised by qualitative changes in
expression of its individual variable exons. These exons however, may be expressed to form a number of molecules, the
alternative splice variants of CD44, which may be structurally and functionally different. Using real-time PCR measurements
with variable exon specific primers we have determined that all are expressed in human melanoma. To permit comparison
between different tumours we identified a stable CD44 variable exon (CD44v) expression pattern, or CD44 ‘fingerprint’. This
was found to remain unchanged in melanoma cell lines cultured in different matrix environments. To evaluate evolution of
this fingerprint during tumour progression we established a scid mouse model, in which the pure expression pattern of
metastatic primary tumours, circulating cells and metastases, non-metastatic primary tumours and lung colonies could be
studied. Our analyses demonstrated, that although the melanoma CD44 fingerprint is qualitatively stable, quantitative
changes are observed suggesting a possible role in tumour progression.
Citation: Raso-Barnett L, Banky B, Barbai T, Becsagh P, Timar J, et al. (2013) Demonstration of a Melanoma-Specific CD44 Alternative Splicing Pattern That
Remains Qualitatively Stable, but Shows Quantitative Changes during Tumour Progression. PLoS ONE 8(1): e53883. doi:10.1371/journal.pone.0053883
Editor: Andrzej T. Slominski, University of Tennessee, United States of America
Received July 27, 2012; Accepted December 4, 2012; Published January 14, 2013
Copyright:  2013 Raso-Barnett et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by grants from Ta´rsadalmi Megu´jula´s Operatı´v Program (Social Renewal Operational Programme) (TA´MOP)-4.2.1./B-09/1/
KMR-2010-0001, Ege´szse´gu¨gyi Tudoma´nyos Tana´cs (Medical Scientific Board of the Hungarian Ministry of Health) (ETT) 087-07/2009 and EGT/Norwegian Financial
Mechanism, HU0125. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rasobarnettlivia@gmail.com
. These authors contributed equally to this work.
Introduction
Elucidation of the role of CD44 and its alternative splice
patterns in melanoma biology has been challenging. Beyond its
standard (CD44S), constitutively expressed region it has ten
variable exons (v1–v10), forming the variable region (CD44v) [1],
which potentially allows for the expression of thousands of
different isoforms of different structure and function. At present,
the expression of 42 CD44 isoforms has been confirmed at mRNA
level, 29 of these have been shown to encode protein. Additionally,
post-translational glycation adds a further layer of diversity to the
possible protein structure and functions. These include binding to
different components of the extracellular matrix, cytokine-binding
and participation in signal pathways of cell growth and migration.
[2–7].
Many of the variable exons’ individual functions have been
examined individually demonstrating significant functional chang-
es in signaling pathways. CD44 is the principal cell surface
receptor for hyaluronate. When v3 is expressed [8] hyaluronate
binding is weaker. Permitting further chondroitin and heparan
sulphate glycosylation, results in the presentation of heparin-
binding growth factors such as HB-EGF, b-FGF and amphir-
egulin. [9] For activating c-met by its ligand, HGF/SF, v6 is
needed and important for the intracellular signal pathway via
MEK and Erk. [10] In Ras pathway-regulated CD44 alternative
splicing, those isoforms containing v6 together with HGF form a
positive feedback loop on Ras, causing the downregulation of non-
v6 containing isoforms [11].
However, there is discrepancy around the data on the role of
CD44 and its isoforms in tumour biology. Despite the fact that it
has been known for a number of years now that healthy tissues
have specific CD44 Alternative Splice Patterns (ASPs) [12], and a
PCR based method has already been proposed to analyse the
different CD44 splice variants [13], there has not been any follow
up to this study. Conversely, most data on CD44 alternative
splicing in neoplasia and tumour progression have focused on the
associations of the expression of single CD44 variable exons.
There are problematic discrepancies in the role of CD44v in
tumour biology.
For example, in colorectal carcinoma some studies indicate that
v2 has a predictive role in progression [14], v3 and v6 play a role
in cancer free survival [15] and v6 again in distant metastases
[16,17]. Other studies have failed to demonstrate any such role
[18,19,20].
Similar discrepancies emerge in the changing patterns of
CD44v expression in human melanoma. Dome et al. demonstrat-
ed the up-regulation of v3 results in a higher visceral metastatic
potential [21] while Pacifico et al. showed that CD44v3 expression
is associated significantly with a better outcome [22]. Again v10
[23] and v6 [24] may be involved in metastasis formation, or not
[25]. One study suggests that human melanomas do not express
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CD44v isoforms at all and only express the CD44S form at a
higher level, and does not correlate with the prognosis of this
tumour type [26]. These varied findings may reflect the focus on
the expression of solitary exons, rather than the profile of all ASPs.
Other studies do analyse the co-expression of two or more
variable exons [27,28], although not as a part of the ASP. In an
alternative splice pattern, many different isoforms are present. The
functional importance of any single variable exon may be
dependent on the full expression pattern. Detecting the presence
of a single, or multiple variable exons across all of these isoforms
does not provide any information as to where these variable exons
are expressed, and crucially what other variable exons are present
alongside. On the other hand, the presence of additional variable
exons on a particular isoform may actually change or not permit
the function of the variable exon in question, and thus without
knowing the entire alternative splice pattern, this restricts what one
can say about detecting the presence of a single variable exon in
these studies.
For the same reason even the ‘co-expression’ of two exons
proven by immunohistochemistry [5,17] does not mean that they
are on the same molecule as the presence of two or more different
CD44 isoforms in the same cell at the same time is also possible.
Although the expression level changes of one variable exon might
still show a correlation with the progression in one tumour type,
there is no such obvious example in the literature as there are lots
of contradictions even during the examination of the same tumour
type.
Some more recent studies have analyzed the role of CD44v
isoforms rather than single exons in tumour progression [29,30],
but not as a part of a complex, finely regulated pattern.
A more holistic view of the alternative splice event is needed to
examine the role of CD44 variants.
This would be a huge practical challenge from tumour to
tumour. We have sought to establish a reliable and reproducible
method to examine this pattern and its possible tumour and/or
progression specificity, since co-expression of exons proven by
immunohistochanistry does not determine whether they are on the
same molecule (and two or more CD44 may be present in the
same cell at the same time) We have used a PCR based method
using five primer pairs to create a simple representation of this
highly complex CD44 expression pattern.
Materials and Methods
Cell Lines and Culture Conditions
The A2058 melanoma cell line was provided by LA Liotta
(NCI, Bethesda, MD). HT168 and HT168M1 lines are
derivatives of A2058 [31]. HT199 [31] was developed in the
1st Department of Pathology and Experimental Cancer
Research (Semmelweis University, Budapest, Hungary).
WM983B [32] and WM35 [32] were gifts from M. Herlyn
(Wistar Institute, Philadelphia, PA). The colorectal carcinoma
cell lines were HT25 [33] (from M. Hendricks, Iowa), HT29
(ECACC 91072201), HCT116 (ICLC HTL95025) and HCR31
[34]. We also used MDA-MB-231 human breast adenocarcino-
ma (ECACC 92020424), PE/CA PJ15 (ECACC 96121230) and
PE/CA PJ41 (ECACC 98020207) human oral squamous cell
carcinomas, K562 human chronic myelogenous leukaemia
(ECACC 89121407) and A431 human vulva squamous carci-
noma (ECACC 85090402) cell lines. The melanocyte (C-12403),
keratinocyte (C-12003) and fibroblast (C-12360) cells were
derived from Promo Cell. The melanoma and colorectal cell
lines were maintained in RPMI 1640 medium supplemented
with 10% fetal bovine serum (Sigma, St. Louis, MD), 2 mM
glutamine, 0.1 mM non-essential amino acids, 1 mM sodium
pyruvate, and 50 mg/ml gentamicin sulfate (all from Gibco
BRL, Life Technologies, Paisley, Scotland). The melanocytes
were maintained in Melanocyte Growth Medium M2 (Promo-
Cell), the keratinocytes in Keratinocyte Media 2 (PromoCell)
and the fibroblasts in Fibroblast Media (PromoCell).
RT-PCR Analysis of CD44 mRNA Expression
Total RNA was isolated from the frozen homogenized
tumour samples and cell cultures from the in vivo experiments
using TRI ReagentTM (SigmaH) according to the manufacturer
instructions. Possible DNA contamination was eliminated using
TURBO DNA-freeTM kit (AmbionH). For reverse transcription
1 ml of 10 mM dNTP mix (Finnzymes, Espoo, Finland) and 1 ml
of random primer-oligo dT were mixed for a final concentration
of 2.5 mM and used with 2 mg of purified total RNA. After
incubating at 70uC for 10 min, 1 ml of M-MLV reverse
transcriptase (200 units/ml), 2 ml of 10x M-MLV RT Buffer
(both from Sigma), 0.5 ml RNase Inhibitor (40 units/ml,
Promega, Madison WI) and 6.5 ml DEPC treated water was
added for 20 ml final volume and incubated at 37uC for 50 min
and then at 85uC for 10 min. The occurrence of reverse
transcription was checked by polymerase chain reaction with b-
actin primers (GTGGGGCGCCCCAGGCACCCA, CTCCTT
AATGTCACGCACGATTTC) as a housekeeping gene. RNA
of the same sample was used as negative control for detection of
DNA contamination and DEPC treated water as non-template
control.
PCR Detection of CD44 Variable Exons
The PCR reaction mixture contained12,5 ml AmpliTaq GoldH
360 Master Mix, 2.5–2.5ml of the appropriate primer pair
designed with Array Designer (Premier Biosoft International)
(Figure S1). 2ml of the cDNA and 5.5 ml DEPC treated water for
the final volume of 25 ml. The cycling conditions were: 97uC for
10 min once, then 95uC for 1 min, 55uC for 1 min, 72uC for
2 min for 35 cycles, 72uC for 10 min. The primer pairs were the
following: S5’- variable exons3’, variable exons5’-S3’,
PCR products were separated using ExperionTM Automated
DNA 1K Kit1ml (Bio-RadH) Electrophoresis System.
PCR Detection and Sequencing of CD44 Fingerprint
The PCR conditions were as described above. The primer pairs
were the following: S5’- S3’, S5’- v33’, v35’- S3’, S5’- v63’, v35’-
v63’ using the exon specific primers (Figures S1, S2 and S3). PCR
products were separated on a 3% agarose gel and detected with
Gel Doc 2000 (Bio-RadH) after ethidium bromide staining.
PCR products were re-isolated from the agarose gel (High Pure
PCR Product Purification Kit, Roche, Mannheim) in the case of
all bands. The DNA sequences were determined by BigDyeH
Terminator v1.1 Cycle Sequencing Kit (Applied BiosystemsTM –
by Life TechnologiesTM).
Cloning the PCR Products from the Fingerprint
The PCR products of the fingerprint were re-isolated from the
2% agarose gel (as above) inserted into vectors in the pGEMH-T
Vector Systems (Promega H) according to the manufacturer’s
instructions. The plasmid DNA was re-isolated using GeneJET
(TM) Plasmid Miniprep Kit (Thermo Scientific) according to the
manufacturer’s instructions and the products were sequenced with
BigDyeH Terminator v1.1 Cycle Sequencing Kit (Applied
BiosystemsTM – by Life TechnologiesTM).
CD44 Alternative Splicing Pattern of Melanoma
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Next-generation Sequencing
During a library preparation the ligated amplicon generation
was used. The PCR products from HT199, A2058 and WM983B
melanoma fingerprints were amplified, purified and their ends
were polished and ligated with Roche 454 multiplex identifier
(MID) adaptors, to generate universal primer binding sites for
emulsion PCR in every sample reactions. The amplicons were
than separated with magnetic Ampure beads (Agencourt) to
eliminate the non-binded adaptors. Emulsification of the ligated
emPCR was done according to the manufacturer’s protocol
(Roche 454). The library was than sequenced with clonal
pyrosequencing technic (454 GS Junior - Roche) with 200 cycles,
in 400 bases read length mode. After sequencing, image processing
and signal processing (amplicon pipeline) the amplicon variant
analyzer software (Roche Diagnostics) was used to demultiplex the
samples after MIDs, to trim the primers and to align the reads to
the reference cDNA sequence. In the case of splice variants the
difference between variants and the complete reference cDNA
sequence can be too high. Therefore the reads were aligned to
every exon separately to identify the real exon combination. The
alignment was successful if there was higher identity than 90% in
more than 20 bases length in every exons. The exon combinations
which have more than 50 reads were reported.
Culturing on Different Matrices
Fibronectin, laminin, collagen IV Matrigel, hyaluronate (each
50 mg/ml) and 0,9% NaCl solution (as control) were administered
into different wells of a 6-well plate. After 3 hours of incubation on
RT, supernatants were removed. 1–1 ml of 56104 cell/ml
suspensions of HT168M1 was administered on the prepared
matrix-films. After 72 hours of incubation, we removed superna-
tants, washed cell-films with EDTA, up-digested cell-films with
tripsin-EDTA, collected up-grown cell suspensions and extracted
total-RNA of cell masses with TRI-Reagent method.
Metastasis Models Using scid Mice
This study was carried out in strict accordance with the
recommendations and was approved by the Semmelweis Univer-
sity Regional and Institutional Committee of Science and
Research Ethics (TUKEB permit number: 83/2009). All surgery
was performed under Nembutal anaesthesia, and all efforts were
made to minimize suffering.
Cultured HT199 and HT168M1 human tumour cells were
injected subcutaneously (5x105/50ml volume) at the same lower
back localisation into 10 newborn and 10 adult scid mice as well as
intravenously into 5 adult scid mice for both cell line. On the 30th
day, the animals were sacrificed by bleeding under anaesthesia.
Primary in vitro cell cultures were formed from the primary
tumour, circulating tumour cells and the lung metastases of the
same animal implanted as a newborn. Also, the primary tumour,
circulating tumour cells and the i.v. transplanted lung colonies
from the adult animals were used to create cell cultures the same
way (Figure S4).
For comparative measurements the different tumours, i.e.
primary tumour, circulating tumour cells, lung metastasis, always
derived from the same animal to allow standardisation of the host.
Quantitative PCR Analysis
For quantitative measurement of the expressed CD44 variable
exons q-PCR reactions were used (iQ SYBRH Green Super-
mix,Bio-Rad), by cycling conditions 3 min at 95uC, then 40 cycles
at 95uC 30 sec, 55uC 30 sec, 72uC 1 min. Starting quantities were
defined on the basis of standard fivefold dilution series (1x-625X)
carried out with control cDNA of A431 human squamous cell
carcinoma) and by normalizing the starting quantities to the
housekeeping b-actin starting quantities from the same cDNS
sample. Three parallel measurements were carried out on each
sample in every case.
Results
CD44 Variable Exons and Possible Isoforms at mRNA
Level
We visualized the expression of CD44 variable exons in HT168
human melanoma by performing PCR reactions pairing the sense
(59) primers of variable exons with the common antisense (39)
primer localized on exon 16 and variable exon’s antisense (39)
primers with the common sense (59) on the standard exon 4. Our
results showed, that all the variable exons, which are considered
variable in databases (v2-v10) were present. Also, this method with
the overlapping sequences allowed us to construct some of the
isoforms (Fig. 1 and Fig. S5), although, this still seems rather
inaccurate as some of the exons seemed to have been of slightly
different size.
This size difference can possibly be explained by the fact that by
next generation sequencing on the same tumour, we identified a
daunting number of small deletions across the CD44 isoforms
(data not shown).
We made further attempts and cloned our PCR products from
A2058 and HT168 M1 human melanoma cell lines, which
resulted in certain isoforms being more dominant and inserting at
a higher rate, but yet again, the full set of the expected/calculated
isoforms could not be identified. However, direct sequencing of
some of the cloned sequences confirmed that v1, is in fact missing
in some of the isoforms, which tied in nicely, with our above
mentioned PCR-based results (Fig. 2A). Furthermore, some
isoforms contained a truncated version of v1 (Fig. 2B).
The CD44 Melanoma Fingerprint
In light of the complexity of CD44 isoform expression simple
method to represent this pattern was developed which included v3
and v6– the exons considered to be of importance for melanoma
progression.
For this purpose, we designed a five primer pair containing
PCR-reaction series using a certain combination of the exon
specific primers, which covered the whole variable region with five
overlapping sequences. The first primer pair was located on the
two standard regions allowing detection of all variable exons (S5’–
S3’, primer pair 1). The second was on exon 4 of the standard
region and v3, which makes possible to detect v2-v3 co-expression
(S5’-v3’, primer pair 2). The third straddles the v3-v10 region by
binding to v3 and exon 16 of the standard region (v35’-S3’, primer
pair 3). The fourth pair was designed to exon 4 and v6 detecting
the co-expression of v2–v5 with v6 (S5’-v63’, primer pair 4). The
fifth one was detecting v4–v5 expression of v3–v6 co-expressing
isoforms by binding to v3 and v6 (v35’-v63’, primer pair 5). The
five PCR products of the same sample were run always in this
same order in every case, so the pattern of the bands were
comparable across all of our samples in the different experimental
models. This bar code-like pattern is what we define as the
‘fingerprint’, a simplified representation of the CD44 ASP.
With this method we examined the CD44 ASP of human
melanoma cell lines (HT168M1, WM35, WM983B, A2058 and
HT199) in culture to establish whether there is a pattern that is
conserved across these genetically different tumours. As it is shown
in Fig. 3A and 4, we found a consistent pattern throughout, which
we refer to as the melanoma fingerprint. Some of the isoforms,
CD44 Alternative Splicing Pattern of Melanoma
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which were predicted from the melanoma fingerprint, based on
the size of the bands, were confirmed by next generation
sequencing. Although the reading frame of 454 GS Junior is
significantly wider than that of similar techniques, its higher limit is
still 400–700 bp. Therefore, even though next generation
sequencing is rather promising, we are still relying on estimations
in the case of larger products. 10 isoforms were confirmed (Fig. 1A)
and a further 26 predicted (Figure S5) as part of the melanoma
CD44 fingerprint.
We then compared this pattern to that of other human tumour
cell lines grown in culture. These included cell lines derived from
human colorectal adenocarcinoma (HT29, HT25, HCT116),
human oral squamous cell carcinoma (PE/CA PJ15 and PE/CA
PJ41), vulval squamous cell carcinoma (A431) and K562 human
erythromyeloblastoid leukemia cell lines.Comparison was also
made with primary cultured human melanocytes, skin keratino-
cytes and skin fibroblasts (Fig. 4). In each case the fingerprint
differed unambiguously from the melanoma fingerprint, raising
the possibility of a melanoma specific isoform expression pattern.
Modeling the Effects of the Microenvironment in vitro
To decide whether the in vitro melanoma CD44 fingerprint is
maintained in vivo despite the influence of the microenvironment,
we compared the CD44 splicing pattern of several, genetically
different human melanoma cell lines (A2058, HT199, WM35,
WM983A, M35) growing on plastic or different matrices. We
also investigated HT168, a cell line cultured from the in vivo
xenograft variant of A2058; HT168M1, a cell line which is the
in vivo selected metastatic version of HT168; WM983B, cultured
from a lymph node metastasis from the patient whose primary
tumour gave rise to WM983A. Since CD44, as a cell surface
glycoprotein, plays an important role in cell-matrix interaction, it
was important to examine whether different matrix components
change the alternative splicing pattern, or whether the ASP is
stable and possibly inherent to melanoma-specific behavior.
Therefore as a first step we determined the CD44 fingerprint of
HT168M1 human melanoma cell line growing in vitro on
different matrices, namely fibronectin, laminin, collagen and
matrigel. As shown in Fig. 5 after 48 hours incubation time the
CD44 fingerprint was found to be unchanged in the case of
every matrix type (Fig. 5). This fingerprint was found to be
consistent through all examined cell lines growing on different
matrices (only HT168M1 shown). It is interesting, that the
fingerprint is retained in the cell lines derived from the primary
tumours and their metastases alike (HT168 versus HT168M1
and WM983A versus WM983B).
The CD44 Melanoma Fingerprint in vivo in Our Animal
Model
As the in vivo microenvironment is far more complex than the
influences of the extracellular matrix, we used an animal model to
evaluate the CD44 melanoma fingerprint in vivo. This model has
been developed by our group, following the observation that semi-
orthotopically (subcutaneously) implanted human melanomas
Figure 1. CD44 isoforms validated by next generation sequencing. A. CD44 isoforms from the qualitative picture of pairing the variable
exon specific primers with the standard region specific ones both 59 and 39 directions in HT168 human melanoma cell line. These isoforms were
validated by next generation sequencing. B. Further validated isoforms from next generation sequencing with the primer pairs of the fingerprint.
doi:10.1371/journal.pone.0053883.g001
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always formed metastases in newborn scid mice (permissive host),
yet never did so in adult ones (nonpermissive host). This model
made it possible to examine the melanoma ‘fingerprint’ during the
metastatic processes.
In vivo expression patterns were evaluated on two human
melanoma cell lines HT199 and HT168M1.
We performed our PCR reaction series on theprimary
subcutaneous tumour, circulating tumour cells obtained from
blood and lung metastases from transplanted newborn scid mice, as
well as the primary subcutaneous tumours from transplanted adult
mice. In addition lung tumours were generated in adult animals by
intravenous injection (Fig. S4).
For HT199 we found that the CD44 fingerprint demonstrated
in vitro was unchanged throughout the sampled sites (Fig. 6B).
These findings do not explain published observations, that the
expression of certain CD44 exons correlate with metastatic
potential. Our results suggest that the CD44 ASP behind the
‘fingerprint’ is the same in all these cases, meaning that the same
isoforms are present. The cited quantitative expression changes of
single variable exons should therefore be explained differently.
We made a further quantitative PCR analysis with our variable
exon specific primers on the same samples. We examined the
quantitative changes of the individual variable exons (VE) during
tumour progression in the in vivo animal models of two genetically
different human melanoma cell lines (HT199, HT168M1). It has
become clear after the first measurements, that the two cell lines
have 3 orders of magnitude difference in their CD44 VE
expression relative to beta-actin housekeeping gene, but despite
this, their malignant potential was practically identical. CD44 in
HT199, the cell line with a low base VE expression, behaved as a
’classical’ metastasis gene. The non-metastatic adult primary (AP),
the metastatic newborn primary (NP) and the lung colony formed
after intravenous injection into adult animals (IVLC), which is also
a form of primary tumour, all expressed the VEs within the same
order of magnitude (Fig. 6A). The circulating tumour cells
(NCTC) and lung metastases (NM) from the animal implanted
as a newborn showed 21 times and 9 times increased expression
respectively.
In the case of HT168M1, which expresses the CD44 VEs in
3 times larger order of magnitude than HT199, the role of
Figure 2. Cloned PCR products from the 59 (exon 4, italic) and 39 (exon 16, bold) primer (squared) combination of CD44 in A2058
human melanoma cell line. Direct sequencing shows a CD44 isoform with no v1 or any other variable exons (A) as well as one with truncated v1
(underlined).
doi:10.1371/journal.pone.0053883.g002
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Figure 3. The CD44 alternative splice pattern of different human tumour cell lines demonstrated by virtual gels and
electropherograms generated by Experion DNA Capillary Electrophoresis System and corresponding agarose gel picture. A.
HT199 human melanoma cell line B. HT29 human colorectal adenocarcinomacell line C. K562 human erythromyeloblastoid leukemia cell line D.
MDA-MB-231 human breast carcinoma cell line.
doi:10.1371/journal.pone.0053883.g003
CD44 Alternative Splicing Pattern of Melanoma
PLOS ONE | www.plosone.org 6 January 2013 | Volume 8 | Issue 1 | e53883
CD44 is more complex. In this case, we created cell cultures
from different localisations of the primary tumour of individual
animals. The individual lung metastases (newborn animals) and
lung colonies (adult animals) of the individual animals were also
cultured separately. The non-metastatic adult primary tumour
(AP) showed a higher expression level of all CD44 VEs than the
metastatis newborn primary tumour (Fig. 7A). The reason
behind the rather large error bars seen on the measurements
from the newborn lung metastases (NM) is that the individual
lung metastases showed huge VE expression level differences.
Cells from the cell line created from the lung metastasis
showing the highest CD44 VE expression level (NM = S1T2,
Figure 7B) were then re-implanted subcutaneously into newborn
animals. Cell cultures were then created from three different
localisations of the primary tumour (PNM) and three random
lung metastases (MPNM) of the chosen animal (Fig. S4). They
showed no difference in CD44 VE expression level compared to
each other, however they showed on average 24 times lower
expression than the cell culture (newborn lung metastasis,
NM = S1T2) of origin. We also consistently detected lower
CD44 VE expression in liver metastases (LMIVLC) from lung
colonies (IVLC), which are practically secondary metastases
(Fig. 7C).
Figure 4. The CD44 alternative splice pattern of different human tumours is different, but preserved throughout samples from the
same the tumour type as it is demonstrated by the agarose gel electropherograms of human melanoma (A 2058, WM983B, WM35
and HT168M), colorectal adenocarcinoma (HT25 and HCT116), oral squamous cell carcinoma (PE/CA PJ15 and PE/CA PJ41) and
vulval squamous cell carcinoma (A431) cell lines. The melnanoma CD44 fingerprint also differs from that of non neoplastic melanocyte,
keratinocyte and fibroblast cell lines as constituents of the microenvironment.
doi:10.1371/journal.pone.0053883.g004
Figure 5. CD44 ‘fingerprint’ of HT168M1 human melanoma cell line growing on different matrices namely plastic (a), fibronectin
(b), laminin (c), collagen (d) and matrigel (e). L stands for molecular weight marker.
doi:10.1371/journal.pone.0053883.g005
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Discussion
Due to the possibility of a large number of different CD44
isoforms present at the same time in the examined sample, it was
important to establish a method that would give a good
representation of them.
Our first step was to determine which variable exons, other than
the ones most studied in the literature, are expressed at mRNA
level in human melanoma. We showed that all the variable exons
are expressed in human melanomas and predicted a number of
paralelly expressed CD44 isoforms. We also found that v1 was
missing from some of the isoforms, although it is not considered as
a variable exon, also that some of the isoforms contained a
truncated v1 exon. This was confirmed by direct sequencing of our
cloned molecules. However, next generation sequencing studies
have surfaced a whole other level of ‘complications’ by identifying
a number of deletions across the variable exons.
As a surrogate for representation of all of the expressed
alternative splice variants of CD44, we developed a method to
determine a ‘fingerprint’ of expression in human melanoma. This
appeared to be stable in cell culture and mouse xenograft models
and differed substantively from that found in colorectal adeno-
carcinoma, squamous cell carcinoma and primary cultures of
human melanocytes, kerationcytes and fibroblasts. This technique
bypasses the attempts to link the expression or co-expression of
individual variable exons to metastasis formation, a strategy which
loses crucial contextual information about the complex ASP
underlying the CD44 protein set. This oversimplification may also
account for some of the contradictory evidence on the associations
of CD44 expression with the generation of a metastatic phenotype
[35,36].
Previous work in our laboratory has shown that under the effect
of host derived selection factors, xenografts of tumour cells
growing in new born scid mice differ in gene expression pattern
than those growing in adult mice. It is not yet clear whether this
pattern is related to formation of metastasis or reflects a
summation of changes resulting from local effects of graft:host
interaction. Adaptation to a new microenvironment is a crucial
factor in the formation of metastasis: This may require events in
changing patterns of gene expression prior to implantation or may
reflect post hoc modification of expression in response to the
metastatic niche. To be able to study the pattern of expression
during tumour progression we have established an experimental
mouse model in which the expression pattern of pure cultured cells
from a primary implanted tumour, circulating cells in the
peripheral blood stream and cells within established metastases
in newborn scid mice from the same, individual animal could be
studied. In addition expression patterns could be compared with
those generated in adult scid mice either as primary tumours as
lung colonies since spontaneous metastases are not formed in this
animal population. We followed the CD44 VE expression changes
Figure 6. Relative quantitative expression of CD44 variable exons in cell cultures from metastatic (newborn) and non-metastatic
human xenograft model (Real-Time PCR measurement) of HT199, a human melanoma cell line of originally low variable exon
expression level. A. The relative expression level of all variable exons is raised in circulating metastatic cells (NCTC) and metastatic cells (NM)
compared to their levels in primary tumours [newborn primary (NP) and adult primary (AP)] and lung colony (IVLC) B. The qualitative fingerprint
(bottom line) remains unchanged.
doi:10.1371/journal.pone.0053883.g006
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during tumour progression of two human melanomas, that express
CD44 VEs at different orders of magnitude, in this experimental
animal model. We found that CD44 VE expression and metastasis
formation showed inverse correlation, similarly to our recent
findings in colorectal carcinomas [37]. The adult primary tumour,
newborn primary tumour and lung colony of HT199, the human
melanoma cell line with low base CD44 VE expression level, all
expressed the variable exons in the same order of magnitude and
within the error bar. However, as only a limited number of cells
within the primary tumour are capable of forming metastasis, the
above finding is not surprising. The dramatic increase in CD44
VE expression level seen in the metastatic tumours means, that the
variants most likely play a role in metastasis formation. The
extreme high level of CD44 VE expression in the circulating
tumour cells of the newborn animals seems to indicate, that their
role is mainly in getting into and/or surviving in the circulation. It
seems, that for the new population of metastatic cells in the target
organ, CD44 VE expression level is not as much or even not at all
important.
The CD44 VE expression level in HT168M1, which has a high
base CD44 VE expression, varies within the metastases, ranging
from barely detectable to approaching the level detected in
circulating tumour cells. When a population with extreme high
CD44 VE level is then re-implanted, the expression level
dramatically decreases in the metastases while the qualitative
picture (fingerprint) remains unchanged.
From these results, we suggest that predicting the role of CD44
variable exon expression in tumour progression is more complex
than previously anticipated. Our qualitative studies identified a
melanoma-specific CD44 ASP, or fingerprint, which is different to
the pattern of other examined tumour types. While this certainly
raises the possibility to use this fingerprint to identify the unknown
primary of metastases, the stability of this fingerprint during
tumour progression also shows that no isoforms changes occur that
could be correlated to metastatic phenotype or prognosis.
However, our real-time PCR measurements suggest that quanti-
tatively, melanoma is not a uniform group and CD44 variable
exon expression levels can follow different patterns. Primary
tumours with low overall CD44 VE expression level harbor
Figure 7. Relative quantitative expression of CD44 variable exons in cell cultures from metastatic (newborn) and non-metastatic
[adult (AP)] human xenograft model (Real-Time PCR measurement) of HT168M1, a human melanoma cell line of originally high
variable exon expression level. A. The relative expression level of all variable exons is raised in certain lung metastasis (NM), when remaines low
or even decreases in other lung metastases resulting in large error bars. It should be noted that the expression level of the primaries from different
localisations [newborn primary (NP), adult primary (AP) and intravenously implanted lung colony (IVLC)] are all comparable, although the slightly
higher expression observed in the adult primary is an unexpected finding. B. We used the lung metastasis from the newborn animal with the highest
CD44 variable exon expression level (NM = S1T2) for subcutaneous re-implantation into another newborn animal. The expression level in the primary
tumour (PNM) and its metastases (MPNM) was 24 times lower on average. C. The liver metastases (LMIVLC) from the intravenously implanted lung
colonies (IVLC) showed a decrease in expression, when compared to the lung colonies (IVLC).
doi:10.1371/journal.pone.0053883.g007
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metastatic clones with high expression level, which appears to be
needed for entering the circulation and forming metastases. On
the other hand, primary tumours with high base CD44 VE
expression also contain metastatic clones, that either have
sufficient CD44 expression or ‘utilize’ other molecules to facilitate
metastasis formation. This, however, does not explain the extreme
low CD44 VE expression levels detected in lung metastases, and
further research in this area is needed. In any case, in both
scenarios the CD44 VE expression level of the true metastatic
clone is not immediately obvious from the overall expression of the
primary tumour, which partially explains the contradicting results
described in the literature.
We hypothesise that the metastatic clone is not the result of ratio
changes or even an ’appearing/disappearing variable exon’, which
might be one of the several factors to give metastatic property to
that clone. Ultimately, these results show that even in one of the
‘most simple’ CD44 fingerprints, melanoma, we cannot talk about
‘CD44’ as a single molecule anymore.
Supporting Information
Figure S1 Sequence and localisation of the exon specific
primers.
(TIF)
Figure S2 Localisation of the primer pairs used to
create the fingerprint.
(TIF)
Figure S3 The melanoma fingerprint. A. Fingerprint with
the product sizes. B. Predicted isoforms based on the qualitative
fingerprint. From the qualitative picture, the following isoforms
can be identified in melanomas: CD44S which does not contain
variable exons and appears as 372bp product in lane 1 of the
fingerprints (a); CD44v3 containing only v3 exon appearing as
385 bp product on lane 2 and 220 bp product in lane 3 of the
fingerprint (b); CD44v6 with also one variable exon (v6) as the
379 bp product of lane 4(c); CD44v2v3 with two expressed
variable exons, v2 and v3 represented by the 514 bp product of
lane 2 (d); CD44v3v6 is also two variable exon containing isoform
which can be identified from the 627 bp product of lane 1, the
505 bp product of lane 4 and the 227 bp product of lane 5 (e) and
CD44v3v4v5v6v9 as the biggest isoform with five expressed
variable exons detected as the 670 bp product of lane 3, the
736 bp product of lane 4 and the 458 bp product of lane 5 (f). As
the variable exons are very similar in size with sometimes only a
few base pair difference other isoforms might be present as well
and the presence of v7, v8, v9 and v10 is also possible. For instance
the 204bp long v10 and the 207 bp long co-expressed v5 and v9
are very hard to distinguish as they would appear as ‘one’ band on
lane three and only v5v9 co-expression can be proved by the
appropriate sized products of lanes 4 and 5. This is further
confirmed by cloning and next generation sequencing.
(TIF)
Figure S4 Schematic structure of the in vivo human
melanoma (HT199 and HT168M1) metastasis animal
model. The same melanoma cell suspension was implanted
subcutaneously into adult and newborn scid mice as well as
intravenously into adult scid mice. The primary adult [(subcuta-
neously (AP) and i.v. implanted (IVLC)] and newborn tumours
(NP) were removed along with the liver (NM) and lung (NLM)
metastases, that were only formed in newborn mice, on the 26th
post-implantation day. Cell cultures were created from all the
above tumours and the circulating tumours cells (NCTC) of
newborn mice. A cell culture created from a single HT168M1
lung metastasis of a newborn mouse was then re-injected
subcutaneously into newborn scid mice and the primary tumour
(PNM) and its lung metastasis (MPNM) were also removed and
cultured on the 26th post implantation day.
(TIF)
Figure S5 Further Hypothesized CD44 isoforms. A.
Hypothesized CD44 isoforms from the qualitative picture of
pairing the variable exon specific primers with the standard region
specific ones both 59 and 39 directions in HT168 human
melanoma cell line. B. Hypothesized isoforms using next
generation sequencing with the primer pairs of the fingerprint
(TIF)
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